Wadhwa M, Dilger P, Tubbs J, Barrowcliffe T, Mahon B, Thorpe R
Division of Immunobiology, NIBSC, South Mimms, Potters Bar, Herts.
Br J Haematol. 1992 Nov;82(3):575-83. doi: 10.1111/j.1365-2141.1992.tb06470.x.
We have continued our previous study of the inhibitory effects of factor VIII concentrates on IL-2 secretion by T cells. Experiments with an extended range of products confirm our previous conclusion that some but not all low, intermediate and high purity concentrates possess inhibitory activity on IL-2 secretion. The inhibition occurs almost immediately after addition of factor VIII concentrate and it was not possible to adsorb inhibitory activity with activated or non-activated cells; this suggests that the mechanism of inhibition involves interference with early T cell activation events rather than simple blocking of cell surface components by inhibitory molecules. The inhibitory components were shown to reside in different molecular weight fractions of concentrates. A strongly inhibitory component of approximately 200 kD and a minor species of approximately 60 kD were identified in strongly inhibitory concentrates. Some products contained a dialysable inhibitory substance which is most likely a salt as it was also present in some formulation buffers. The proportions of the inhibitory components varied widely between products. We have found that the pattern of inhibition using in vitro systems reflects that observed using a mouse in vivo antigen challenge method. In addition we have shown that the previously reported concentrate mediated inhibition of lectin induced low affinity IL-2 receptor (CD25) is mainly a consequence of diminished IL-2 secretion rather than a 'direct' effect on CD25 expression. Considering the wide variation between products of the same purity group, caution should be exercised in drawing conclusions concerning the immunosuppressive effects of a particular type of concentrate in haemophilia patients from study with only one product from that group.
我们继续了之前关于凝血因子VIII浓缩物对T细胞分泌白细胞介素-2(IL-2)的抑制作用的研究。使用更多种类产品进行的实验证实了我们之前的结论,即部分而非全部的低、中、高纯度浓缩物对IL-2分泌具有抑制活性。在添加凝血因子VIII浓缩物后,抑制作用几乎立即出现,并且无法通过活化或未活化的细胞吸附抑制活性;这表明抑制机制涉及干扰T细胞早期活化事件,而非抑制性分子简单地阻断细胞表面成分。结果显示,抑制成分存在于浓缩物的不同分子量组分中。在强抑制性浓缩物中鉴定出一种约200 kD的强抑制性成分和一种约60 kD的次要成分。一些产品含有可透析的抑制性物质,很可能是一种盐,因为它也存在于一些配方缓冲液中。不同产品中抑制成分的比例差异很大。我们发现,体外系统中的抑制模式反映了在小鼠体内抗原攻击法中观察到的情况。此外,我们还表明,先前报道的浓缩物介导的对凝集素诱导的低亲和力IL-2受体(CD25)的抑制作用,主要是IL-2分泌减少的结果,而非对CD25表达的“直接”影响。鉴于同一纯度组产品之间存在广泛差异,仅根据该组中一种产品的研究就对血友病患者中特定类型浓缩物的免疫抑制作用得出结论时应谨慎。